6 minute read
Jul. 17, 2023

A squaramide-containing, Insurmountable CCR6 Antagonist for Ulcerative Colitis.


oral, insurmountable, selective CCR6 antagonist Ph. I in HV completed, in Ph. I for ulcerative colitis from directed screening for novel negative allosteric modulators J. Pharm. Exp. Ther., May 4, 2023 Pfizer, Cambridge, MA


MOTY Nominees

Molecule of the Year